On the afternoon of May 8, 2024, Glotope Advanced Pharmaceutical Technology Ltd and BoomRay held a strategic cooperation signing ceremony at Glotope's Wuxi R&D and Production site. The signing was officiated by the Chairman of BoomRay, Mr. Bo Shan, and the Chief Operating Officer of Glotope, Mr. Ge Bai.

On April 19, 2024, at the Inaugural XDC New Drug Conference's grand gala event "Sky of Bio-Conjugates," Glotope was honored with the title of "Pioneer Enterprise in Nuclear Medicine Infrastructure." This recognition acknowledges Glotope's outstanding contributions to the field of nuclear medicine research and production.

On April 18, 2024, the anticipated Inaugural XDC New Drug Conference kicked off, with Glotope hosting the "Comprehensive Nuclear Medicine Development Lecture Hall" as one of the event's highlights. The audience was highly engaged. Numerous industry experts participated, uncovering high-potential targets in nuclear medicine research, sharing updates on the radiopharmaceutical industry and regulations, and discussing full lifecycle strategies for radiopharmaceutical development. The goal was to provide professional solutions to common challenges in the nuclear medicine industry and accelerate the advancement of high-potential radiopharmaceutical projects.

In the past six months, several major multinational corporations have invested heavily in acquiring radiopharmaceutical companies, including Eli Lilly's acquisition of POINT Biopharma, Bristol-Myers Squibb's purchase of RayzeBio, and AstraZeneca's partnership with Fusion Pharmaceuticals. These significant deals have sparked a global wave of investment in the radiopharmaceutical sector, also known as nuclear medicine.Glotope, a China-based CRO/CDMO platform with a global perspective, will be hosting the "Nuclear Medicine Development Lecture Hall" on April 18.